In vivo optical imaging of vascular changes and vascular leak is an emerging modality for studying altered physiology in a variety of different cancers and inflammatory states. In oncology, increases in tumor vascular permeability can be an early indicator of tumor angiogenesis. In inflammatory disease increased vascular permeability can indicate alterations in fluid homeostasis in an acute edema response or in chronic organ conditions.
PerkinElmer’s AngioSense® NIR fluorescent probes are designed to evaluate vascular changes to better understand various disease states or provide valuable information on effects of drug candidates earlier in the development process.
For laboratory use only. This product is intended for animal research only and not for use in humans.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
AngioSense 680EX NIR fluorescent imaging probe is an in vivo blood pool vascular agent that remains localized in the vasculature for extended periods of time (0-4 hrs) enabling imaging of vascularity, perfusion, and vascular permeability at a wavelength of 680 nm. The probe accumulates in tumors and arthritic joints at 24 hrs. AngioSense 680EX can be used as a single probe or multiplexed with probes at other wavelengths.
|Fluorescent Agent Type||Vascular|
|Optical Imaging Classification||Fluorescence Imaging|
|Quantity in a Package Amount||1.0 Units|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Vascular disease, Angiogenesis, Arthritis, Inflammation, Oncology/Cancer|
|Unit Size||1 Vial (10 doses)|
|Wave Length||680 nm|
Optical-based in vivo imaging of vascular changes and vascular leak is an emerging modality for studying altered physiology in a variety of different cancers and inflammatory states. A number of fluorescent imaging probes that circulate with the blood, but have no target selectivity, have been used to detect tumor leakiness as an indication of abnormal tumor vasculature. Inflammation is also characterized by distinct vascular changes, including vasodilation and increased vascular permeability, which are induced by the actions of various inflammatory mediators. This process is essential for facilitating access for appropriate cells, cytokines, and other factors to tissue sites in need of healing or protection from infection. This application note investigates the use of three fluorescent imaging probes, to detect and monitor vascular leak and inflammation in preclinical mouse breast cancer models.
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
Cancer chemotherapy can produce severe side effects such as suppression of immune function and damage to heart muscle, gastrointestinal tract, and liver. If serious enough, tissue injury can be a major reason for late stage termination of drug discovery research projects, so it is becoming more important to integrate safety/toxicology assessments earlier in the drug development process. There are a variety of traditional serum markers, tailored mechanistically to specific tissues, however there are no current non-invasive assessment tools that are capable of looking broadly at in situ biological changes in target and non-target tissue induced by chemical insult.
AngioSense® 680 EX is a fluorescent in vivo blood pool imaging agent. AngioSense® 680 EX is a nearinfrared labeled fluorescent macromolecule that remains localized in the vasculature for extended periods of time and enables imaging of blood vessels and angiogenesis.
AngioSense 680 EX in vivo imaging agent protocol for preparing mice for imaging, preparing AngioSense 680EX agent, injections of agent into mice, imaging injected mice on IVIS and FMT imaging systems
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.